Objective-To assess the effectiveness and safety of amiodarone in the treatment of junctional ectopic tachycardia (JET) after open heart surgery in children. Patients-Between January 1990 and December 1991, 16 consecutive patients aged 6 days to 14 years with JET associated with significant haemodynamic impairment after cardiopulmonary bypass were treated with amiodarone as the principal antiarrhythmic drug. Interventions-Amiodarone 5 mglkg was administered intravenously over one hour and the same dose was subsequently infused over 12 hours. This was reviewed every 12 hours and repeated as necessary until a satisfactory heart rate and stable haemodynamics were achieved. Atrial pacing was used whenever possible to provide atrioventricular synchrony. Results-Except for one patient with a JET rate of 160/min, the maximum JET rate ranged from 180/min to 245/min with a mean(SD) of 200 (20) 
after open heart surgery in children. Patients-Between January 1990 and December 1991, 16 consecutive patients aged 6 days to 14 years with JET associated with significant haemodynamic impairment after cardiopulmonary bypass were treated with amiodarone as the principal antiarrhythmic drug. Interventions-Amiodarone 5 mglkg was administered intravenously over one hour and the same dose was subsequently infused over 12 hours. This was reviewed every 12 hours and repeated as necessary until a satisfactory heart rate and stable haemodynamics were achieved. Atrial pacing was used whenever possible to provide atrioventricular synchrony. Results-Except for one patient with a JET rate of 160/min, the maximum JET rate ranged from 180/min to 245/min with a mean(SD) of 200 (20) /min. After amiodarone, the heart rates reduced to a mean(SD) of 170 (20) , 164 (27), 158 (27), 157 (24), and 153 (19) /min at two, four, eight, 12 , and 24 hours respectively. A reduction in tachycardia rate allowing atrial pacing was achieved in 10 patients by two hours. Haemodynamic variables improved in most patients with an increase in mean systolic blood pressure by an average of 15 mm Hg and a decrease in atrial filling pressures by an average of 3*5 mm Hg at four hours after amiodarone administration. There were three deaths: one was a moribund patient who died soon after the onset of JET and the other two deaths were not directly related to (fig 2) . Of the 15 patients who survived the tachycardia, a reduction to a rate at which atrial pacing was possible was achieved in 10 patients by two hours; only one of 15 patients had a heart rate more than 1 80/min at eight hours.
Prolonged atrial pacing was used in 10 of the 16 patients. Of the other six patients, two returned to sinus rhythm three and five hours after amiodarone and pacing was used only briefly; in one with alternating nodal and sinus rhythm (rate 120/min) haemodynamic function was satisfactory and not improved with pacing; one could not be captured; one died soon after the onset of JET; and in one patient significant bradycardia with hypotension developed eight hours after amiodarone was started and demand ventricular pacing was begun as he had no atrial wires.
Haemodynamic variables were assessed four hours after amiodarone administration. Blood pressure increased in most patients ( fig  2) , with the systolic blood pressure increasing from a mean (SD) of 75 (12) group.bmj.com on July 7, 2017 -Published by http://heart.bmj.com/ Downloaded from patient who had truncus arteriosus repair initially and developed JET at reoperation for residual ventricular septal defect. He subsequently died after a third operation was required for aortic valve replacement. Amiodarone was not identified as contributing significantly to death in any of these three patients.
Discussion
Junctional ectopic tachycardia after cardiac surgery may be a life threatening arrhythmia in infants, although it is mostly well tolerated in adult patients. The incidence is unknown but retrospective review of 154 children undergoing open heart surgery from 1983 to 1984 by Grant et al identified 12 cases of JET with significant haemodynamic impairment.'
Chaikitpinyo et al, from our unit, observed junctional tachycardia at a rate above 1 50/min in 7% of 395 patients returning to the intensive care unit after open heart surgery.8 Till and Rowland reported 11 patients in a two year nine month review period.4
This arrhythmia is thought to result from enhanced automaticity within the bundle of His.'69 Cellular damage associated with the operation around the region of the bundle of His has been implicated in its pathogenesis. It occurs in few infants and children having an operation in this region, however. Delay after depolarisation has also been proposed as a possible mechanism.9 Occasionally, JET can occur in patients where the operation was remote from the bundle of His,5 suggesting other indirect mechanisms; we have postulated that stretching of the node may alter its electrical behaviour. In our series, 14 of 16 patients had an operation near the bundle of His and two patients had an operation remote from it (patients 7 and 16).
Physical measures have been used to attempt control of JET. Hypothermia has been used to slow the heart rate by depressing automaticity.451'0 Balagi et al reduced the mean junctional rate from 211 to 146 in seven mostly postoperative patients by lowering their core temperature to 32-340C." Antiarrhythmic drugs were not given in four of these. Improved blood pressure and urine output was documented but three patients nevertheless died. As in our series and that of Till and Rowland,4 the relative contributions to death of the arrhythmia in itself, the underlying cardiac disorder, and multiple perioperative factors is hard to determine.
Augmentation of cardiac output by establishing atrioventricular synchrony was well documented by Till and Rowland, who reported the use of a combination of hypothermia, amiodarone, and other drugs to slow the junctional rate. 4 They achieved immediate benefit by coupling atrial stimulation to the preceding His bundle ectopic focus. We agree with this group that early recognition and immediate treatment will maximise salvage and we believe that the staged protocol reported earlier by Sholler et al has potential disadvantages.5
The postoperative and congenital forms of JET have generally been refractory to conventional antiarrhythmic drugs. Grant et aP reported the successful use of digoxin. A favourable response was not seen by others,5 12 however. Propranolol and verapamil are generally ineffective,5 12 and their use is also limited by their depressant effect on the myocardium. Newer class lc drugs such as propafenone'2 and flecainide'2-'4 have had some success but their known negative inotropic effects limit their use in the critical postoperative period. Waldo et at'5 and Slysmans et al 16 described paired ventricular pacing as a means of reducing the heart rate, and surgical ablation of the bundle of His has been reported as a last resort procedure. '7 Amiodarone hydrochloride is a class 3 antiarrhythmic drug that prolongs the repolarisation and refractory period of atrial, nodal, and ventricular tissues, thereby giving it a wide range of activity.'8 Its effect in JET may relate to its inhibition of abnormal automaticity, and the increase in the refractory period of the atrioventricular node and His-Purkinje system. When given intravenously, a loading dose is required because of the rapid disappearance of the drug from plasma during the distribution phase, which appears to be large. Continuous infusion is then necessary to sustain steady state plasma drug concentrations of about 1 ,ug/ml.'9 The drug is metabolised to desethylamiodarone, the activity of which is uncertain, and excreted through the liver. The dose regimen was based on the manufacturer's recommendation, though lower maintenance doses were given. Hypotension was not definitely recognised after the initial infusion, but we were prepared to use volume expansion rather than give further inotropes that may increase the heart rate. Although prolongation of the QT interval is expected with long term administration by mouth, this was not recognised in our patients receiving amiodarone intravenously.
Amiodarone has been used to treat congenital JET20-22 intravenously in the acute phase and by mouth to prevent recurrence. Villain et al, in a multicentre study, reported 14 patients with congenital JET who were treated with amiodarone with eight successes and three partial successes. 20 Till et al had a subset of seven patients who were given amiodarone postoperatively, with reduction in the tachycardia rate in four.3
Over the two year period of our review, amiodarone was used as the principal drug to control JET and was supplemented with atrial pacing. Two thirds of the patients had reduction of JET rate to less than 180/min by two hours and nearly all patients within four hours. It was then possible to use overdrive atrial pacing to provide atrioventricular synchrony. We found that the junctional rate was reduced as the myocardium recovered and the dose of inotropic drugs decreases, whether or not amiodarone has been used. We would therefore prefer that atrial pacing wires are available in all patients who have had an operation under cardiopulmonary bypass, but transoesophageal pacing was possible in one patient when they were not.
Recovery to sinus rhythm seemed to be spontaneous and probably not directly influenced by amiodarone. Our rationale for treatment, however, was the reduction of the JET rate first and then the production of atrial conducted rhythm by atrial pacing. Further improvement in cardiac and metabolic function allows spontaneous return of sinus rhythm, which generally occurs within three to seven days. Because of the long time needed for this drug to reach equilibrium, any correlation of blood concentration with clinical response would probably be difficult to establish.
No serious complications were encountered. When compared with other series of patients with JET1457 the mortality in our group of patients was relatively low and could not be attributed directly to either adverse drug reaction or failure of the treatment.
We believe that amiodarone is an effective and safe method of controlling JET after cardiac surgery in children.
